Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure"

Transcription

1 The Journal of International Medical Research 2007; 35: Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure V ATAY 1, T CEYHAN 2, İ BASER 2, S GUNGOR 2, Ü GOKTOLGA 2 AND M MUHCU 1 1 Department of Obstetrics and Gynaecology, GATA Haydarpasa Training Hospital, Istanbul, Turkey; 2 Department of Obstetrics and Gynaecology, GATA Training Hospital, Ankara, Turkey This study investigated ovarian function and adnexial pathology following total abdominal hysterectomy with preservation of both ovaries compared with that in a control group. Data from 29 patients who had undergone total abdominal hysterectomy at age 40 years and 42 menopausal patients with no previous ovarian pathology were evaluated retrospectively. The mean (± SD) age of menopause was 49.7 ± 1.5 years in the total abdominal hysterectomy group and 50.1 ± 1.3 years in the control group; this difference was not statistically significant. The incidences of cyst and hydrosalpinx were 31% and 6.9%, respectively, in the total abdominal hysterectomy group and 44.8% and 0%, respectively, in the control group. The increased incidence of cysts in the total abdominal hysterectomy group was statistically significant. In conclusion, patients who undergo total abdominal hysterectomy without oophorectomy do not experience premature menopause. Preservation of the ovaries may avoid the disadvantages of hormone replacement therapy at the expense of a higher risk of developing adnexial pathology. KEY WORDS: HYSTERECTOMY; OOPHORECTOMY; MENOPAUSE; OVARIAN FUNCTION; ADNEXIAL PATHOLOGY; OVARIAN CYSTS; HYDROSALPINX Introduction The question as to whether normal ovaries should be removed or preserved during abdominal hysterectomy in pre-menopausal women has not yet been resolved. There is no consensus concerning the removal or conservation of the ovaries, nor whether there should be a cut-off age. 1 The main problem associated with conservation of the ovaries is that ovarian cancer may subsequently develop. 2 The risk of cancer development in the remaining ovaries, together with the difficulty in diagnosing this disease, has led to the practice in the UK and USA of oophorectomy being performed during hysterectomies in women > 40 years old. 3,4 Cessation of ovarian function is associated with an increased risk of osteoporosis and coronary artery disease. Other complaints, which are associated with lack of oestrogen production, include vasomotor hot flushes, urogenital, anal or sexual dysfunction, and emotional disturbances. The consequences of 416

2 oestrogen deprivation can be minimized with hormonal replacement, but a large trial has shown that treatment for up to 5.2 years was not beneficial overall and was associated with early risk for coronary heart disease, continuing risk for stroke and venous thromboembolism, and increasing risk for breast cancer with increasing duration. 5 In this retrospective study, we investigated ovarian function and pathology in patients who had undergone total abdominal hysterectomy with preservation of the ovaries, compared with a control group. Patients and methods PATIENTS Data from patients who had undergone total abdominal hysterectomy without oophorectomy at the age of 40 years were evaluated retrospectively. After undergoing total abdominal hysterectomy, these patients had been followed up regularly for at least 8 years in the outpatient clinic: pelvic structures were evaluated with endovaginal sonography and ovarian function was determined from serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH) and oestradiol (E2). Data from a control group consisting of randomly chosen post-menopausal patients who required regular follow-up visits were used for comparison. Any record of ovarian pathology was noted in the control patients; they did not have any other significant gynaecological abnormalities. Exclusion criteria for both patients and controls consisted of previous pelvic operation, infertility treatment, elevated tumour markers, the presence of pelvic pathology, polycystic ovarian syndrome, smoking, a family history of early menopause, ovarian cancer and breast cancer. In addition, in the total abdominal hysterectomy group, patients showing a gonadotropin level within the post-menopausal range at the time of operation were excluded from the study. The study was approved by the Ethics Committee of GATA Training Hospital, Ankara, Turkey. ASSESSMENT OF OVARIAN FUNCTION The onset of menopause was determined from changes in the levels of FSH, LH and E2 in serum samples measured with an autoanalyser (Aysym, Abbott Laboratories, Illinois, USA) using a microparticle enzyme immunoassay. Serum FSH and LH levels 20 miu/ml were considered to be a sign of impaired ovarian function. DATA ANALYSIS Results were reported as the mean ± SD. Differences between the total abdominal hysterectomy group and the control group were tested for significance using the independent samples t-test and Fisher s exact test. Statistical analysis was performed using SPSS for Windows 12.0 (SPSS Inc., Chicago, Illinois, USA). A P-value < 0.05 was considered to be statistically significant. Results Data from 29 patients who had undergone total abdominal hysterectomy without oophorectomy and 42 controls randomly chosen from 283 possible subjects were evaluated. In the total abdominal hysterectomy group, the mean age at hysterectomy was 39.1 ± 0.7 years. All women were operated on for benign conditions: 18 for uterine leiomyoma, eight for dysfunctional uterine bleeding, two for endometrial hyperplasia and one for chronic pelvic pain. The age at menopause in the two groups is 417

3 54 53 Menopausal age (years) n = 26 TAH n = 42 Control FIGURE 1: Age at menopause in patients undergoing total abdominal hysterectomy (TAH) with preservation of the ovaries and in controls, showing the range, upper and lower quartiles and median values (P > 0.05, independent samples t-test) shown in Fig. 1. The mean age of menopause in the total abdominal hysterectomy group was 49.7 ± 1.5 years; this was not significantly different to the mean menopausal age in the control group (50.1 ± 1.3 years). Adnexial pathologies detected during follow-up visits in the two groups are given in Table 1. Significantly more ovarian cysts developed in the total abdominal hysterectomy group than in controls (P < 0.005). Re-laparotomy and bilateral oophorectomy were performed in three of the nine patients in the total abdominal hysterectomy group who developed ovarian cysts. Histopathological findings were compatible with mucinous cystadenoma in one patient and serous cystadenoma in the remaining two patients. TABLE 1: Adnexial pathologies following total abdominal hysterectomy (TAH) with preservation of the ovaries compared with controls TAH (n = 29) Controls (n = 42) No. % No. % P-value a Cyst < Hydrosalpinx NS a Fisher s exact test. NS, not statistically significant (P > 0.05). 418

4 Discussion Women undergoing hysterectomy for benign pelvic lesions encounter the dilemma of whether to preserve macroscopically normallooking ovaries. The effect of hysterectomy on the function of preserved ovaries was studied by Siddle et al. 6 They found that the mean age of ovarian failure in the hysterectomized group (45.4 ± 4.0 years) was significantly lower than that in the non-hysterectomized control group (49.5 ± 4.04 years). They attributed this finding to a potential decrease in blood flow to the ovaries due to operational trauma. In contrast, our present study, showed that the age of menopause was comparable in the total abdominal hysterectomy and control groups (49.7 ± 1.5 and 50.1 ± 1.3 years, respectively). Bukovsky et al. 7 examined ovarian function following abdominal hysterectomy with or without unilateral oophorectomy; they reported that 35% of those undergoing unilateral oophorectomy, but only one of the patients with both ovaries preserved, demonstrated impaired ovarian function 6 months after the operation. Thus, if the ovaries are to be preserved at hysterectomy, it would seem to be beneficial to preserve both ovaries. Reports from the Woman s Health Initiative (WHI) study group regarding hormone therapy have raised questions about the efficacy and safety of two particular regimens of postmenopausal hormone treatment, 5,8 resulting in an epidemic of fear and distrust amongst women and physicians. Over-inflated negative data emerging from the oestrogen plus progestin treatment arm of the WHI study have frightened women and given rise to difficult emotions. At present, most physicians agree that the benefits of hormone replacement therapy include a decrease in the incidence of osteoporotic fractures and colorectal cancer, whereas the risks include an increase in breast cancer, coronary heart disease, stroke, thromboembolic events, cognitive impairment, dementia and cholecystitis. Despite these risks, hormone replacement therapy should still be considered the best treatment option for the short-term therapy of menopausal symptoms. When used long-term, however, it should be remembered that, in addition to the medical implications, it is associated with considerable financial cost. Several reports have suggested that the post-menopausal ovary is an important site of androgen synthesis. 9,10 In the present study, there was no difference between the total abdominal hysterectomy and control groups with regard to menopausal age. Preservation of both ovaries in patients aged 40 years may, therefore, not only reduce the need for exogenous oestrogen, but may also maintain a site of post-menopausal androgen synthesis. Zalel et al. 11 reported a high incidence (37/73 patients; 50.7%) of various pelvic lesions following hysterectomy with preservation of at least one ovary compared with hysterectomy without ovarian preservation (5/91 patients; 5.5%). Four of the 37 women who developed pelvic lesions following hysterectomy with preservation of at least one ovary underwent re-operation, whereas none of the five women who developed pelvic lesions following hysterectomy without ovarian preservation required further surgery. In the present study, the incidences of cyst and hydrosalpinx in the total abdominal hysterectomy group were 31.0% and 6.9%, respectively. Although these incidences were significantly higher than those in the control group, they are lower than those reported by Zalel et al. 11 Namnoum et al. 12 determined the risk of re-operation and/or recurrence of symptoms after hysterectomy for the treatment of endometriosis. Among 138 women, the ovaries were preserved in 39 and all ovarian tissue was 419

5 removed in 109. Of those whose ovaries were preserved, 62% had recurrent pain and 31% required intervention. The authors concluded that the women with ovarian preservation had six times the risk of developing recurrent pain and an eight-fold greater risk of re-operation. None of the cases in the present study underwent total abdominal hysterectomy for endometriosis. The most important benefit of removing the ovaries together with the uterus is that the risk of ovarian carcinoma is reduced to zero. It has been estimated that prophylactic oophorectomy could save between 7% and 15% of patients from developing ovarian carcinoma. 3,13 Hysterectomy on its own, however, seems to be associated with a reduction in the risk of ovarian cancer. A study of ovarian cancer and steroid hormones in women aged years found a reduction in the relative risk of ovarian cancer 10 years after hysterectomy, but this reduction was no longer present after two decades. 14 Another study from the USA showed a progressive reduction in the protection conferred by hysterectomy against borderline ovarian tumours with increasing interval from surgery 15 and, in a study by Whittemore et al. 16 the reduction in ovarian cancer risk was still evident but no longer significant 10 years after surgery. In conclusion, this study showed that patients who underwent total abdominal hysterectomy without oophorectomy did not experience premature menopause. We believe, therefore, that a conservative approach involving preservation of the ovaries is preferable in patients 40 years of age who require hysterectomy. Received for publication 4 December 2006 Accepted subject to revision 12 January 2007 Revised accepted 27 March 2007 Copyright 2007 Field House Publishing LLP References 1 Dicker RC, Scally MJ, Greenspan LR, et al: Hysterectomy among women of reproductive age. Trends in the United States, JAMA 1982; 248: Parazzini F, Negri E, La Vecchia C, et al: Hysterectomy, oophorectomy, and subsequent ovarian cancer risk. Obstet Gynecol 1993; 81: Gibbs EK: Suggested prophylaxis for ovarian cancer. A 20 year report from cases at Butterworth Hospital. Am J Obstet Gynecol 1971; 111: Sightler SE, Boike GM, Estape RE, et al: Ovarian cancer in women with prior hysterectomy: a 14- year experience at the University of Miami. Obstet Gynecol 1991; 78: Rossouw JE, Anderson GL, Prentice RL, et al, for the Women s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial. JAMA 2002; 288: Siddle N, Sarrel P, Whitehead M: The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril 1987; 47: Bukovsky I, Halperin R, Schneider D, et al: Ovarian function following abdominal hysterectomy with and without unilateral oophorectomy. Eur J Obstet Gynecol Reprod Biol 1995; 58: Anderson GL, Limacher M, Assaf AR, et al, for the Women s Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women s Health Initiative randomized controlled trial. JAMA 2004; 291: Adashi EY: The climacteric ovary as a functional gonadotropin-driven androgenproducing gland. Fertil Steril 1994; 62: Ushiroyama T, Sugimoto O: Endocrine function of the peri- and postmenopausal ovary. Horm Res 1995; 44: Zalel Y, Lurie S, Beyth Y, et al: Is it necessary to perform a prophylactic oophorectomy during hysterectomy? Eur J Obstet Gynecol Reprod Biol 1997; 73: Namnoum AB, Hickman TN, Goodman SB, et al: Incidence of symptom recurrence after hysterectomy for endometriosis. Fertil Steril 1995; 64: Jacobs I, Oram D: Prophylactic oophorectomy. 420

6 Br J Hosp Med 1987; 38: Cramer DW, Hutchison GB, Welch WR, et al: Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983; 71: Harlow BL, Weiss NS, Roth GJ, et al: Casecontrol study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 1988; 48: Whittemore AS, Wu ML, Paffenbarger RS Jr, et al: Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 1988; 128: Address for correspondence Associate Professor V Atay Gülhane Askeri Tip Akademisi Haydarpaşa Eğitim Hastanesi, Kadin Hastaliklari ve Doğum Servisi, TR Usküdar, Istanbul, Turkey

Menopause and HRT. John Smiddy and Alistair Ledsam

Menopause and HRT. John Smiddy and Alistair Ledsam Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation

More information

5. Summary of Data Reported and Evaluation

5. Summary of Data Reported and Evaluation 326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal

More information

Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D

Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D Menopause and Cancer How does menopause affect a woman s cancer risk? Ø Menopause does not cause cancer.but risk of developing

More information

Ardhanu Kusumanto Oktober Contraception methods for gyne cancer survivors

Ardhanu Kusumanto Oktober Contraception methods for gyne cancer survivors Ardhanu Kusumanto Oktober 2017 Contraception methods for gyne cancer survivors Background cancer treatment Care of gyn cancer survivor Promotion of sexual, cardiovascular, bone, and brain health management

More information

North American Menopause Society (NAMS)

North American Menopause Society (NAMS) North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College

More information

06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:

06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence: Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion

More information

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy? Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force

More information

Oncologist. The. Review and Commentary. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate

Oncologist. The. Review and Commentary. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate The Oncologist Review and Commentary Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate M. STEVEN PIVER Department of Gynecologic Oncology, Gilda

More information

BSO, HRT, and ERT. No relevant financial disclosures

BSO, HRT, and ERT. No relevant financial disclosures BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures

More information

Research. Breast cancer represents a major

Research. Breast cancer represents a major Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.

More information

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes

More information

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased

More information

Surgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk

Surgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk Surgery to Reduce the Risk of Ovarian Cancer Information for Women at Increased Risk Centre for Genetics Education NSW Health 2017 The Centre for Genetics Education NSW Health Level 5 2C Herbert St St

More information

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive

More information

Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors

Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors REPRODUCTIVE SURGERY Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors Yoav Yinon, M.D., Mario E. Beiner, M.D., Walter

More information

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan Female Genital Tract Lab Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan Ovarian Pathology A 20-year-old female presented with vague left pelvic pain. Pelvic exam revealed

More information

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health

More information

- Ovarian cancer accounts for 3% of all cancers in females - About 80% of ovarian tumors are benign, and these occur mostly in young women between

- Ovarian cancer accounts for 3% of all cancers in females - About 80% of ovarian tumors are benign, and these occur mostly in young women between Ovarian Tumors - Ovarian cancer accounts for 3% of all cancers in females - About 80% of ovarian tumors are benign, and these occur mostly in young women between the ages of 20 and 45 years and may be

More information

Menopause - a summary of management

Menopause - a summary of management Page 1 of 5 Menopause - a summary of management Original article by: May Su Resources Menopause treatment algorithm The Jean Hales Foundation for women's heath. Menopause, a treatment algorithm. (Australian

More information

Infertility: A Generalist s Perspective

Infertility: A Generalist s Perspective Infertility: A Generalist s Perspective Learning Objectives Fertility and Lifestyle: Patient education Describe the basic infertility workup Basic treatment strategies unexplained Heather Huddleston, MD

More information

Unexpected Gynecologic Findings at Laparotomy. Susan A. Davidson, MD University of Colorado, Denver School of Medicine

Unexpected Gynecologic Findings at Laparotomy. Susan A. Davidson, MD University of Colorado, Denver School of Medicine Unexpected Gynecologic Findings at Laparotomy Susan A. Davidson, MD University of Colorado, Denver School of Medicine Adnexal Mass: Gyn Etiologies Uterine Leiomyomas Pregnancy Malignancy Tubal Pregnancy

More information

Hysterectomy : A Clinicopathologic Correlation

Hysterectomy : A Clinicopathologic Correlation Bahrain Medical Bulletin, Vol. 28, No.2, June 2006 Hysterectomy : A Clinicopathologic Correlation Layla S Abdullah, FRCPC* Objective : To study the most common pathologies identified in hysterectomy specimens

More information

Outline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013

Outline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013 Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort

More information

Hormonal Control of Human Reproduction

Hormonal Control of Human Reproduction Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with

More information

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH How to cite this article: CHOWTA N K,SEBASTIAN J,CHOWTA M N.COMPARATIVE STUDY OF MENOPAUSAL SYMPTOMS IN POST MENOPAUSAL AND PERIMENOPAUSAL WOMEN.Journal of Clinical

More information

RESEARCH ARTICLE. Hariyono Winarto*, Bismarck Joel Laihad, Laila Nuranna. Abstract. Introduction

RESEARCH ARTICLE. Hariyono Winarto*, Bismarck Joel Laihad, Laila Nuranna. Abstract. Introduction DOI:http://dx.doi.org/10.7314/APJCP.2014.15.5.1949 RESEARCH ARTICLE Modification of Cutoff Values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for Ovarian Cancer Detection

More information

Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L

Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Record Status This is a critical abstract of an economic

More information

Before you prescribe

Before you prescribe Initiating hormone replacement therapy (HRT) / menopausal hormone therapy (MHT) Dr Sonia Davison Jean Hailes Consultant Endocrinologist Before you prescribe Ensure there are no contraindications to HRT/MHT

More information

Epidemiology of Ovarian Cancer

Epidemiology of Ovarian Cancer 1 Epidemiology of Ovarian Cancer Karim Elmasry and Simon A. Gayther Translational Research Labs, Windeyer Institute, University College London, UK. Introduction Primary carcinoma of the ovary is the fourth

More information

Menopausal hormone therapy includes various forms, Review

Menopausal hormone therapy includes various forms, Review Review Annals of Internal Medicine Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations Heidi

More information

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are

More information

Menopause: diagnosis and management NICE guideline NG23. Published November 2015

Menopause: diagnosis and management NICE guideline NG23. Published November 2015 Menopause: diagnosis and management NICE guideline NG23 Published November 2015 1 Full title: Menopause : diagnosis and management Available at: http://www.nice.org.uk/guidance/ng23 Guideline published

More information

Primary and secondary amenorrhoea

Primary and secondary amenorrhoea BRITISH MEDICAL JOURNAL VOLUME 294 28 MARCH 1987 815 Clinical Aalgorithms Primary and secondary amenorrhoea S FRANKS Amenorrhoea, which is usually defined as no periods for six months or more, occurs in

More information

Traditional Chinese Medicine (TCM) in the Management of Menopausal Symptoms/Conditions

Traditional Chinese Medicine (TCM) in the Management of Menopausal Symptoms/Conditions Introduction www.womenshealthclinic.co.uk Traditional Chinese Medicine (TCM) in the Management of Menopausal Symptoms/Conditions XY Zhang, PhD MD Women s Health Clinic, London, UK Email: xzhang@womenshealthclinic.co.uk

More information

POSTMENOPAUSAL ESTROGEN USE

POSTMENOPAUSAL ESTROGEN USE ORIGINAL CONTRIBUTION Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women Carmen Rodriguez, MD, MPH Alpa V. Patel, MPH Eugenia E. Calle, PhD Eric J. Jacob,

More information

Increased human epididymis protein 4 in benign gynecological diseases complicated with chronic renal insufficiency patients

Increased human epididymis protein 4 in benign gynecological diseases complicated with chronic renal insufficiency patients Increased human epididymis protein 4 in benign gynecological diseases complicated with chronic renal insufficiency patients Y.W. Lv, L. Yang, M. Zhang, L.H. Jiang, J.H. Niu, J. Hou and X.H. Cui Department

More information

bleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the

bleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the Studies on the diagnosis of endometria cancer in women with postmenopausal bleeding. Studies naar de diagnostiek va endometriumcarcinoom bij vrouwen m postmenopauzaal bloedverlies. Studies on the diagnosis

More information

International Journal of Current Medical And Applied Sciences.vol.1. Issue: 1, 2013, PP 11-15

International Journal of Current Medical And Applied Sciences.vol.1. Issue: 1, 2013, PP 11-15 International Journal of Current Medical And Applied Sciences.vol.1. Issue: 1, 2013, PP 1115 Polycystic Ovarian Syndrome Patients in Relation to Clinical and Endocrine Parameters and Association of BMI

More information

HRT & Menopause Where Do We Stand Now?

HRT & Menopause Where Do We Stand Now? HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by

More information

A case of extremely rare ovarian tumor: Primary ovarian adenomyoma

A case of extremely rare ovarian tumor: Primary ovarian adenomyoma Kawasaki Medical Journal 233 A case of extremely rare ovarian tumor: Primary ovarian adenomyoma Shoji KAKU, Takuya MORIYA, Naoki KANOMATA, Tsuyoshi ISHIDA Yangsil CHANG, Norichika USHIODA, Yuichiro NAKAI

More information

Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women

Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women Maturitas 50 (2005) 19 29 Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women Toshiyuki Yasui a,, Hirokazu Uemura a, Yuka Umino

More information

Hormones and cancer -risks and benefits

Hormones and cancer -risks and benefits Hormones and cancer -risks and benefits Terhi Piltonen M.D., PhD., Associate Professor Consultant, Clinical Researcher for the Finnish Medical Foundation Department of Obstetrics and Gynecology PEDEGO

More information

Palm Beach Obstetrics & Gynecology, PA

Palm Beach Obstetrics & Gynecology, PA Palm Beach Obstetrics & Gynecology, PA 4671 S. Congress Avenue, Lake Worth, FL 33461 561.434.0111 4631 N. Congress Avenue, Suite 102, West Palm Beach, FL 33407 Endometriosis The lining of the uterus is

More information

In 1981, we published results from a case-control. study involving 881 cases and 863 controls. not associated with any substantial overall risk,

In 1981, we published results from a case-control. study involving 881 cases and 863 controls. not associated with any substantial overall risk, Br. J. Cancer (1986) 54, 825-832 Menopausal oestrogens and breast cancer risk: An expanded case-control study L.A. Brinton, R. Hoover & J.F. Fraumeni, Jr Environmental Epidemiology Branch, National Cancer

More information

Improving Fertility in Women with PCOS

Improving Fertility in Women with PCOS Improving Fertility in Women with PCOS William D. Schlaff, M.D. Paul and Eloise Bowers Professor and Chairman Dept. of Obstetrics & Gynecology Sidney Kimmel Medical College Thomas Jefferson University

More information

Background. Background. Background. Background 2/2/2015. Endometriosis-Associated Ovarian Cancer: Malignant Transformation of Endometriosis

Background. Background. Background. Background 2/2/2015. Endometriosis-Associated Ovarian Cancer: Malignant Transformation of Endometriosis Endometriosis-Associated Ovarian Cancer: Malignant Transformation of Endometriosis I have no disclosures. Marcela G. del Carmen, MD, MPH Associate Professor Division of Gynecologic Oncology EOC is gynecologic

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium anastrozole 1mg tablets (Arimidex ) No. (198/05) AstraZeneca UK Ltd New indication: for adjuvant treatment of postmenopausal women with hormone receptorpositive early invasive

More information

The preferred treatment for osteoporosis

The preferred treatment for osteoporosis Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the

More information

Primary Neonatal and paediatric Consultant Dr M Gnanabalan Operating Paediatric Surgeon Dr P Balamourugane Paediatric Pathologist Dr Seetha lakshmi

Primary Neonatal and paediatric Consultant Dr M Gnanabalan Operating Paediatric Surgeon Dr P Balamourugane Paediatric Pathologist Dr Seetha lakshmi Dr C K Janaki Raman DNB Pediatrics Trainee Department of Pediatrics Mehta Childrens Hospital Primary Neonatal and paediatric Consultant Dr M Gnanabalan Operating Paediatric Surgeon Dr P Balamourugane Paediatric

More information

ORIGINAL INVESTIGATION. Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer. increasingly used in developed

ORIGINAL INVESTIGATION. Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer. increasingly used in developed ORIGINAL INVESTIGATION Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer Eva Glud, MD, PhD; Susanne K. Kjaer, DMSc; Birthe L. Thomsen, MSc; Claus Høgdall, PhD; Lise Christensen,

More information

Ovarian Cancer Causes, Risk Factors, and Prevention

Ovarian Cancer Causes, Risk Factors, and Prevention Ovarian Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for ovarian cancer.

More information

Comparison of anti-mullerian hormone level in nonendometriotic benign ovarian cyst before and after laparoscopic cystectomy

Comparison of anti-mullerian hormone level in nonendometriotic benign ovarian cyst before and after laparoscopic cystectomy Iran J Reprod Med Vol. 13. No. 3. pp: 149-154, March 2015 Original article Comparison of anti-mullerian hormone level in nonendometriotic benign ovarian cyst before and after laparoscopic cystectomy Sedigheh

More information

Subtotal Versus Total Abdominal Hysterectomy

Subtotal Versus Total Abdominal Hysterectomy Bahrain Medical Bulletin, Vol.23, No.3, September 2001 Subtotal Versus Total Abdominal Hysterectomy Hassan Jamal, MD, CABOG* Z Amarin, MD, MSc, FRCOG** Objectives: To study subtotal compared to total hysterectomy.

More information

Uterine Fibroids: No financial disclosures. Current Challenges, Promising Future. Off-label uses of drugs. Alison Jacoby, MD.

Uterine Fibroids: No financial disclosures. Current Challenges, Promising Future. Off-label uses of drugs. Alison Jacoby, MD. Uterine Fibroids: Current Challenges, Promising Future Alison Jacoby, MD Professor, Dept of Obstetrics, Gynecology and Reproductive Sciences No financial disclosures Off-label uses of drugs The BIG Questions

More information

Preventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004

Preventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004 Preventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004 I am also PRO!... because HT does not increase breast cancer, and overall, its benefits out weight

More information

Benton Franklin County Medical Society 31st Annual CME Seminar

Benton Franklin County Medical Society 31st Annual CME Seminar Management of Current HT/ET and SERM Recommendations Benton Franklin County Medical Society 31st Annual CME Seminar February 21, 2015 Kennewick, Washington Spokane steoporosis Dr. Lynn Kohlmeier Lynn Kohlmeier,

More information

2. Gynecologic Pathology 28. Ovarian Pathology

2. Gynecologic Pathology 28. Ovarian Pathology 2. Gynecologic Pathology 28 Ovarian Pathology Physiologic Cysts Ovarian cysts can be visualized sonographically in women of all ages. The presence of a simple (unilocular, anechoic, thin-walled) cystic

More information

Hormonal Contraception: Asian View. Hormonal Contraception: Asian View: focused on Chinese View. Prof.Dr.Xiangyan Ruan, MD.PhD

Hormonal Contraception: Asian View. Hormonal Contraception: Asian View: focused on Chinese View. Prof.Dr.Xiangyan Ruan, MD.PhD Asian View Prof.Dr.Xiangyan Ruan, MD.PhD Beijing Obstetrics & Gynecology Hospital, Capital Medical University (China) WHO Collaborative Centre - Director of Dept. of Gynecological Endocrinology & & - Fertility

More information

Prevention, Diagnosis and Treatment of Gynecologic Cancers

Prevention, Diagnosis and Treatment of Gynecologic Cancers Prevention, Diagnosis and Treatment of Gynecologic Cancers Jubilee Brown MD and Pamela T. Soliman MD, MPH Department of Gynecologic Oncology and Reproductive Medicine University of Texas MD Anderson Cancer

More information

Epidemiological and Clinical Aspects of Hormone Therapy

Epidemiological and Clinical Aspects of Hormone Therapy Epidemiological and Clinical Aspects of Hormone Therapy Background Treatment with sex hormones is widely used in Sweden, and has been so for many years. Most women use some kind of sex hormones for various

More information

Study of Hypothyroidism in Women with Abnormal Uterine Bleeding

Study of Hypothyroidism in Women with Abnormal Uterine Bleeding IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 4 Ver. VI (Apr. 2016), PP 12-18 www.iosrjournals.org Study of Hypothyroidism in Women with

More information

Managing the adnexae at the time of hysterectomy for benign gynaecological disease

Managing the adnexae at the time of hysterectomy for benign gynaecological disease Managing the adnexae at the time of hysterectomy for benign gynaecological disease This statement has been developed and reviewed by the Women s Health Committee and approved by the RANZCOG Board and Council.

More information

BRCA mutation carrier patient: How to manage?

BRCA mutation carrier patient: How to manage? BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE

More information

Evaluation of Ovarian Lesions Inducing Endometrial Hyperplasia or Carcinoma in a Tertiary Care Hospital in Southern India

Evaluation of Ovarian Lesions Inducing Endometrial Hyperplasia or Carcinoma in a Tertiary Care Hospital in Southern India Original Article Evaluation of Ovarian Lesions Inducing Endometrial Hyperplasia or Carcinoma in a Tertiary Care Hospital in Southern India Shalinee Rao, Shivani Rao 1, Sharda Lall 2, Raghavan Narasimhan

More information

Polycystic ovarian disease and Endometriosis

Polycystic ovarian disease and Endometriosis Polycystic ovarian disease and Endometriosis Objectives: At the end of this lecture, the student should be able to: Know the clinicopathologic features of endometriosis with special emphasis on: definition,

More information

Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators

Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen

More information

Clinical Efficacy and Complications of Uterine Artery Embolization in Symptomatic Uterine Fibroids

Clinical Efficacy and Complications of Uterine Artery Embolization in Symptomatic Uterine Fibroids Global Journal of Health Science; Vol. 8, No. 7; 2016 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Clinical Efficacy and Complications of Uterine Artery Embolization

More information

Female Sexual Hormones Indications and Therapy

Female Sexual Hormones Indications and Therapy Female Sexual Hormones Indications and Therapy In puberty, a woman has about 400,000 ovules, at the age of 40-44 years about 17,000 only. On average, each grown-up woman (still having ovulation) loses

More information

Article begins on next page

Article begins on next page Virilization and Enlarged Ovaries in a Postmenopausal Woman Rutgers University has made this article freely available. Please share how this access benefits you. Your story matters. [https://rucore.libraries.rutgers.edu/rutgers-lib/52404/story/]

More information

NICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23

NICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23 Menopause: diagnosis and management NICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Chapter 100 Gynecologic Disorders

Chapter 100 Gynecologic Disorders Chapter 100 Gynecologic Disorders Episode Overview: 1. Describe the presentation and RF for Adnexal torsion 2. List the imaging findings of adnexal torsion (US vs CT) 3. What is the management of adnexal

More information

Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes*

Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes* FERTILITY AND STERILITY Vol. 59, No.5, May 1993 Copyright e 1993 The American Fertility Society Printed on acid-free paper in U.S.A. Prevention of endometrial hyperplasia by progesterone during long-term

More information

What is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this...

What is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this... PCOS What is PCOS? You'll be amazed when you read this... What is PCOS?. Who is at risk? How to get tested? What are the complications. Is there a cure? What are the right ways to eat? What lifestyle changes

More information

Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases

Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases J Gynecol Oncol Vol. 20, No. 3:158-163, September 2009 DOI:10.3802/jgo.2009.20.3.158 Original Article Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases

More information

Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol]

Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol] Página 1 de 7 Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol] Kalantaridou SN, Calis KA, Nelson LM. This protocol should be cited

More information

Minimally Invasive Hysterectomies: A Survey of Current Practices. amongst members of the International Society for Gynaecologic Endoscopy

Minimally Invasive Hysterectomies: A Survey of Current Practices. amongst members of the International Society for Gynaecologic Endoscopy Minimally Invasive Hysterectomies: A Survey of Current Practices amongst members of the International Society for Gynaecologic Endoscopy Abstract Study Objective This study aimed to explore the current

More information

Infertility F REQUENTLY A SKED Q UESTIONS. Q: Is infertility a common problem?

Infertility F REQUENTLY A SKED Q UESTIONS. Q: Is infertility a common problem? Infertility (female factors). In another one third of cases, infertility is due to the man (male factors). The remaining cases are caused by a mixture of male and female factors or by unknown factors.

More information

Topic 24: Estrogens and Female Reproductive Drugs

Topic 24: Estrogens and Female Reproductive Drugs Topic 24: Estrogens and Female Reproductive Drugs I. Contraceptives A. Estrogen-Progestin Contraceptives Note all of these drugs contain one estrogen (listed first) and one progestin Drug to know: ethinyl

More information

Khunte VP et al; Spectrum of Lesions in Hysterectomy specimens

Khunte VP et al; Spectrum of Lesions in Hysterectomy specimens ORIGINAL ARTICLE Spectrum of Lesions in Hysterectomy Specimens and their Preoperative Correlation Khunte VP 1, Kulkarni V 2, Gahine R 3, Indoria CS 4 1. Assistant Professor, Department of Obstetrics and

More information

Management of Menopausal Symptoms

Management of Menopausal Symptoms Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of

More information

What s New in Menopause Management. Objectives

What s New in Menopause Management. Objectives What s New in Menopause Management Leslee L. Subak, MD Professor of Obstetrics, Gynecology & Reproductive Science University of California, San Francisco Objectives Define the menopause transition Review

More information

Clinicopathological Study of Uterine Leiomyomas: A Multicentric Study in Rural Population

Clinicopathological Study of Uterine Leiomyomas: A Multicentric Study in Rural Population DOI 10.1007/s13224-015-0773-y ORIGINAL ARTICLE Clinicopathological Study of Uterine Leiomyomas: A Multicentric Study in Rural Population Maitri Raghavendra Kulkarni 1 Indranil Dutta 2,3 Dilip Kumar Dutta

More information

Clear cell carcinoma arising from abdominal wall endometriosis: a unique case with bladder and lymph node metastasis

Clear cell carcinoma arising from abdominal wall endometriosis: a unique case with bladder and lymph node metastasis Liu et al. World Journal of Surgical Oncology 2014, 12:51 WORLD JOURNAL OF SURGICAL ONCOLOGY CASE REPORT Open Access Clear cell carcinoma arising from abdominal wall endometriosis: a unique case with bladder

More information

Reproduction and Development. Female Reproductive System

Reproduction and Development. Female Reproductive System Reproduction and Development Female Reproductive System Outcomes 5. Identify the structures in the human female reproductive system and describe their functions. Ovaries, Fallopian tubes, Uterus, Endometrium,

More information

Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy

Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human

More information

CLIMARA 25 CLIMARA 50 CLIMARA 75 CLIMARA 100

CLIMARA 25 CLIMARA 50 CLIMARA 75 CLIMARA 100 REGISTERED PACKAGE INSERT SCHEDULING STATUS S4 PROPRIETARY NAMES AND DOSAGE FORMS CLIMARA 25 CLIMARA 50 CLIMARA 75 CLIMARA 100 Estradiol transdermal systems COMPOSITION Climara 25: Climara 50: Climara

More information

Pharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting Disclosure

Pharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting Disclosure Pharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting 2015 Disclosure The faculty and planners for this activity, as well as the CME staff, do not have any relevant

More information

This includes bone loss, endometrial cancer, and vasomotor symptoms.

This includes bone loss, endometrial cancer, and vasomotor symptoms. Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to

More information

Hormone therapy for menopausal vasomotor symptoms

Hormone therapy for menopausal vasomotor symptoms Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert

More information

HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D

HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D All of the hormones in your body are designed to work together. This is God s plan. Therefore, if one is altered, or deficient, it will affect the actions

More information